OYAGEN, INC.
Sangivamycin, an adenosine nucleoside analog antiviral therapeutic for COVID-19
- Sector
- Biotech
- Headquarters
- Rochester, NY
- Latest Form D
- $345K, Dec 2017
- Total capital
- $5M
- Federal grants
- $3M
- 8 awards · 2018–2024
- Rank in peer group#344 of 514
- Private capital raised
- $2.1M
- 2 Form D · last Dec 2017
- 107 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 30 pending · first 2021
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$298K
- Federal grantHealth and Human S · Phase I · IND-Enabling Development of a Small Molecule COVID Therapeutic$300K
- Federal grantHealth and Human S · Phase I · High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$299K
- Federal grantHealth and Human S · Phase I · IND-Enabling Development of a Small Molecule COVID Therapeutic$300K
- Federal grantHealth and Human S · Phase I · Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$286K
- Federal grantHealth and Human S · Phase I · Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$573K
- Federal grantHealth and Human S · Phase I · Preclinical Development of HIV Vif Antagonists$300K
- Private capital raisedForm D · SEC · 2nd filing$345K
- Private capital raisedForm D · SEC · 1st filing$1.7M
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Preclinical Development of HIV Vif Antagonists$600K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#109 · top 21%
- Linked publications#81 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Harold SmithResearcherExecutive Officer, DirectorLinked by 3 patents
- Ryan BennettResearcherExecutive OfficerLinked by $1.2M in grants as PI
- Jose CoronasDirectorNamed in SEC Form D filings
- Kevin PhelpsDirectorNamed in SEC Form D filings
- Richard McCloskeyDirectorNamed in SEC Form D filings
- Richard OgdenDirectorNamed in SEC Form D filings
Show all 9 people
- Roscoe MooreDirectorNamed in SEC Form D filings
- Thomas FitzgeraldExecutive Officer, PromoterNamed in SEC Form D filings
- William CarpenterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 33- GrantedMethod For Treating Coronavirus InfectionsUSPTOUS 11,779,585
- PendingMethod For Treating Arenaviridae InfectionsUSPTOApplication 17918964
- GrantedMethod For Treating Coronavirus InfectionsUSPTOUS 11,738,025
Show all 33 patent records
- Method For Treating Coronavirus InfectionsOct 10, 2023 · US 11,779,585Granted
- Method For Treating Arenaviridae InfectionsSep 14, 2023 · Application 17918964Pending
- Method For Treating Coronavirus InfectionsAug 29, 2023 · US 11,738,025Granted
- Method For Treating Poxviridae InfectionsJul 27, 2023 · Application 17918970Pending
- Compounds, Compositions, And Methods For Treating Human Immunodeficiency VirusJan 6, 2022 · Application 17474895Pending
- Compounds, Compositions, And Methods For Treating Human Immunodeficiency VirusSep 14, 2021 · US 11,116,762Granted
- Camptothecin Derivatives As Anti-hiv Agents And Methods Of Identifying Agents That Disrupt Vif Self-associationOct 29, 2020 · Application 16819130Pending
- Small Molecules As Anti-hiv Agents That Disrupt Vif Self-association And Methods Of Use ThereofOct 1, 2015 · Application 14433228Pending
- Method For Treating Coronavirus InfectionsApplication 62987846Pending
- Method For Treating Coronavirus InfectionsApplication 62970087Pending
- Triazolophthalazine Compounds, Use As Anti-human Immunodeficiency Virus Inhibitors Of Hiv Vif-dependent Degradation Of APOBEC3, And Methods For Preparation ThereofApplication PCTUS2018067609Pending
- Triazolophthalazine Compounds, Use As Anti- Human Immunodeficiency Virus Inhibitors Of Hiv Vif-dependent Degradation Of APOBEC3, And Methods For Preparation ThereofApplication 62644872Pending
- Compounds, Compositions, And Methods For Treating Human Immunodeficiency VirusApplication PCTUS2018012098Pending
- Camptothecin Derivatives As Anti-hiv Agents And Methods Of Use ThereofApplication 62442374Pending
- Methods Of Treating And Inhibiting Ebola Virus InfectionApplication 62420474Pending
- Small Molecule Vif Dimerization Antagonists As Anti-hiv Agents And For Use As Hiv/aids TherapeuticsApplication PCTUS2015019147Pending
- Camptothecin Derivatives As Anti-hiv Agents And Methods Of Identifying Agents That Disrupt Vif Self-associationApplication PCTUS2014043974Pending
- Small Molecule Vif Dimerization Antagonists As Anti-hiv Agents And For Use As Hiv/aids TherapeuticsApplication 62013550Pending
- Combination Therapy For Treating Hiv And AidsApplication PCTUS2014037935Pending
- Small Molecule Vif Dimerization Antagonists As Anti-hiv Agents And For Use As Hiv/aids TherapeuticsApplication 61949175Pending
- Small Molecules As Anti-hiv Agents That Disrupt Vif Self-association And Methods Of Use ThereofApplication PCTUS2013063571Pending
- Camptothecin Derivatives As Anti-hiv Agents And Methods Of Identifying Agents That Disrupt Vif Self-associationApplication 61838574Pending
- Combination Therapy For Treating Hiv And AidsApplication 61822835Pending
- Small Molecules As Anti-hiv Agents That Disrupt Vif Self-association And Methods Of Use ThereofApplication 61807480Pending
- Small Molecules As Anti-hiv Agents That Disrupt Vif Self-association And Methods Of Use ThereofApplication 61709471Pending
- Peptide And Treatment For HIV-1 InfectionApplication PCTUS2007024790Pending
- Method For Treating Poxviridae InfectionsApplication PCTUS2021027354Pending
- Method For Treating Arenaviridae InfectionsApplication PCTUS2021027352Pending
- Method For Treating Coronavirus InfectionsApplication PCTUS2021016472Pending
- Method For Treating Coronavirus InfectionsApplication PCTUS2020028567Pending
- Method For Treating Coronavirus InfectionsApplication 63009972Pending
- Method For Treating Poxviridae InfectionsApplication 63010021Pending
- Method For Treating Arenaviridae InfectionsApplication 63010007Pending
Recent research by its founders
- Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase20233 cites
- Corrigendum to “Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase” [Antivir. Res. 218 (2023) 105716–105728, doi: 10.1016/j.antiviral.2023.105716]20230 cites
- Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties202120 cites
Related companies, and why
- PROMAKHOS THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- SYNTIS BIO INCSimilar federal contract value in Biotech · null in contracts
- BEAT BIOTHERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- PNA INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
- Arrevus, Inc.Similar federal contract value in Biotech · null in contracts
- TOPAZ BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .